Causes of Hypercalcemia and Hyperuricemia
Hypercalcemia Causes
The differential diagnosis of hypercalcemia is fundamentally organized by PTH level, which distinguishes between PTH-dependent and PTH-independent etiologies 1.
PTH-Elevated or Inappropriately Normal Hypercalcemia
- Primary hyperparathyroidism (PHPT) - accounts for approximately 90% of hypercalcemia cases in outpatients 2
- Familial hypocalciuric hypercalcemia (FHH) - caused by inactivating mutations in CASR, GNA11, or AP2S1 genes 1
- Malignancy with PTH-rP secretion - common in epidermoid and neuroendocrine tumors, causes humoral hypercalcemia of cancer with characteristic renal hypophosphatemia 1
PTH-Suppressed or Low Hypercalcemia (6 Main Categories) 1
Malignant causes:
- Osteolytic metastases from solid tumors (breast cancer) or multiple myeloma - typically accompanied by hyperphosphatemia 1
- Local osteolysis via NFKappaB-RANK-ligand pathway 1
Hypervitaminosis D:
- Excessive calcitriol production by granulomatous tissue or macrophages via extra-renal 1-alpha-hydroxylase in granulomatosis, lymphoma, or pneumocystosis 1
- May present with elevated phosphatemia due to increased intestinal phosphate absorption 1
Genetic causes:
- Childhood idiopathic hypercalcemia type 1 (CYP24A1 gene variants) 1
- Mahvash syndrome (GCGR gene variants) 1
- Williams-Beuren syndrome (chromosome 7 microdeletion) - 15% develop moderate infantile hypercalcemia 1
- Jansen's metaphyseal chondrodysplasia (activating PTH1R variants) 1
- Hypophosphatasia (ALPL gene mutation with low alkaline phosphatase) 1
Immobilization-related:
- Occurs 4-6 weeks after immobilization in young adults post-spinal trauma or elderly poly-pathological patients
- Mediated by increased sclerostin inhibiting Wnt pathway, causing preponderance of osteoclastic resorption 1
Endocrine causes:
- Hyperthyroidism - direct thyroid hormone action on bone resorption 1
- Acute adrenal insufficiency - hypercalcemia typically <3 mmol/L from dehydration and metabolic acidosis 1
- Pheochromocytoma - direct catecholamine action on bone or PTH-rP secretion 1
- Acromegaly - hypercalcemic tendency from increased calcitriol production via IGF-1 action 1
Drug-induced:
- Thiazide diuretics, lithium, excessive vitamin D or calcium supplementation 1, 2
- Immune checkpoint inhibitors, denosumab discontinuation 2
Other causes:
- Cirrhosis (chronic or acute decompensation) - linked to inflammatory cytokines and prostaglandins, associated with increased mortality 1
Critical Diagnostic Algorithm
First, measure PTH:
- Elevated/normal PTH → PHPT or FHH (check calciuria, genetic testing)
- Suppressed PTH (<20 pg/mL) → evaluate for malignancy, vitamin D excess, endocrinopathies, drugs, immobilization 2
Common pitfall: Calciuria alone cannot reliably distinguish FHH from PHPT due to overlapping ranges 1. FHH subjects have normal calciuria, not truly "hypocalciuric" 1.
Hyperuricemia Causes
Hyperuricemia is defined as serum urate >6.8-7.0 mg/dL and results from either uric acid overproduction or underexcretion 3.
Primary Causes
- Idiopathic hyperuricemia - most common, often associated with metabolic syndrome 3
- Genetic disorders - enzyme defects affecting purine metabolism
Secondary Causes
Increased uric acid production:
- Myeloproliferative disorders
- Lymphoproliferative disorders
- Hemolytic anemias
- Psoriasis
- High purine diet (red meat, seafood, alcohol especially beer)
Decreased uric acid excretion:
- Chronic kidney disease - most important cause of reduced excretion 3, 4
- Medications: thiazide and loop diuretics (most common drug cause), low-dose aspirin 3
- Hypertension 3, 4
- Metabolic syndrome and obesity 3
- Type 2 diabetes 3
- Lead nephropathy
- Lactic acidosis
- Ketoacidosis
Cardiovascular Risk Context
Elevated serum uric acid is independently associated with cardiovascular mortality, heart failure, stroke, and faster CKD progression 4. However, routine urate-lowering therapy for asymptomatic hyperuricemia has not shown clear cardiovascular benefit in randomized trials 4.
Management Threshold
For symptomatic gout or very high cardiovascular risk, target serum urate 180-300 μmol/L (3-5 mg/dL) with febuxostat as first-line therapy 5. ULT should be customized according to pathophysiologic type (overproduction vs. underexcretion) 5.
Key distinction: Asymptomatic hyperuricemia requires risk stratification before treatment, whereas gout with tophi or recurrent flares mandates urate-lowering therapy 3, 5.